共 50 条
- [21] Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36_SUPPL) : 438780 - 438780Xu, Rui-HuaWang, FengShen, LinGuo, WeijianLiu, TianshuLi, JinQin, ShukuiBai, YuxianChen, ZhendongWang, JufengPan, YueyinShu, YongqianZhao, FuyouCheng, YingYe, FengGu, KangshengZhang, TaoPan, HongmingZhong, HaijunSu, Weiguo
- [22] PACLITAXEL AS SECOND-LINE CHEMOTHERAPY IN ADVANCED OR RECURRENT GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAANNALS OF ONCOLOGY, 2011, 22 : v48 - v49Machado, KarimeToloi, DiegoNebuloni, DanielaRibeiro, SuilaneRiechelmann, RachelFukushima, JuliaFreitas, HelanoHoff, Paulo
- [23] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialGastric Cancer, 2022, 25 : 197 - 206Charles S. FuchsMustafa ÖzgüroğluYung-Jue BangMaria Di BartolomeoMario MandalaMin-Hee RyuLorenzo FornaroTomasz OlesinskiChristian CaglevicHyun C. ChungKei MuroEric Van CutsemAnneli ElmePeter Thuss-PatienceIan ChauAtsushi OhtsuPooja BhagiaAnran WangChie-Schin ShihKohei Shitara
- [24] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Kojima, TakashiMuro, KeiFrancois, EricHsu, Chih-HungMoriwaki, ToshikazuKim, Sung-BaeLee, Se-HoonBennouna, JaafarKato, KenLin, ShenQin, Shi-QuiFerreira, PaulaDoi, ToshihikoAdenis, AntoineEnzinger, Peter C.Shah, Manish A.Wang, RuixueBhagia, PoojaKang, S. PeterMetges, Jean-Philippe
- [25] Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Shah, Manish A.Bennouna, JaafarShen, LinEnzinger, Peter C.Li, QiaoCsiki, IldikoKoshiji, MinoriDoi, Toshihiko
- [26] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialLANCET, 2018, 392 (10142): : 123 - 133Shitara, KoheiOzguroglu, MustafaBang, Yung-JueDi Bartolomeo, MariaMandala, MarioRyu, Min-HeeFornaro, LorenzoOlesinski, TomaszCaglevic, ChristianChung, Hyun C.Muro, KeiGoekkurt, ErayMansoor, WasatMcDermott, Raymond S.Shacham-Shmueli, EinatChen, XinqunMayo, CarlosKang, S. PeterOhtsu, AtsushiFuchs, Charles S.
- [27] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Lorenzen, SylvieThuss-Patience, Peter C.Pauligk, ClaudiaGoekkurt, ErayEttrich, Thomas JensLordick, FlorianReichardt, PeterStahl, MichaelKopp, Hans-GeorgHegewisch-Becker, SusannaReichart, AlexanderAlguel, HanaBichev, DmitryKestler, AngelikaHacker, UlrichZiegenhagen, Nicolas StephanMueller, ChristianHermes, BarbaraAl-Batran, Salah-Eddin
- [28] Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Fuchs, Charles S.Ozguroglu, MustafaBang, Yung-JueDi Bartolomeo, MariaMandala, MarioRyu, Min-heeFornaro, LorenzoOlesinski, TomaszCaglevic, ChristianChung, Hyun CheolMuro, KeiVan Cutsem, EricElme, AnneliThuss-Patience, Peter C.Chau, IanOhtsu, AtsushiBhagia, PoojaWang, AnranShih, Chie-SchinShitara, Kohei
- [29] The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancerANNALS OF ONCOLOGY, 2019, 30Metges, J.Francois, E.Shah, M.Adenis, A.Enzinger, P.Kojima, T.Muro, K.Bennouna, J.Hsu, C.Moriwaki, T.Kim, S.Lee, S.Kato, K.Shen, L.Qin, S.Ferreira, P.Wang, R.Bhagia, P.Kang, S.Doi, T.
- [30] Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Patnaik, AmitaSocinski, Mark A.Gubens, Matthew A.Gandhi, LeenaStevenson, JamesBachman, Robert D.Bourque, JenniferGe, Joy YangIm, EllieGadgeel, Shirish M.